| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Pfizer Inc. | Modified RNA (modRNA) vaccine | Influenza | Phase 2 | Data Released | Intramuscular | Antiviral |
| Pfizer Inc. | Danuglipron (PF-06882961) - (PK Study) | Obesity | Phase 2 | Trial Discontinued | Oral | Endocrinology |
| Pfizer Inc. | Lotiglipron (PF-07081532) | Obesity and Type 2 diabetes mellitus (T2DM) | Phase 2 | Oral | Endocrinology | |
| Pfizer Inc. | ORIC-533 and elranatamab | Multiple myeloma | Phase 2 | Enrollment Conclusion | ORIC-533 oral elranatamab subcutaneous | Oncology |
| Pfizer Inc. | PF-06760805 (GBS6) | Streptococcus Vaccine | Phase 2 | Intramuscular | Immunology | |
| Pfizer Inc. | MRx0518 with bavencio (avelumab) | 1L Urothelial carcinoma | Phase 2 | Intravenous | Oncology | |
| Pfizer Inc. | BNT162b5 | COVID-19 vaccine | Phase 2 | Intramuscular | COVID-19 | |
| Pfizer Inc. | Ervogastat (PF-06865571) and clesacostat (PF-05221304) | Metabolic dysfunction-associated steatohepatitis (MASH) with liver fibrosis | Phase 2 | Oral | Gastroenterology |